Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

Phase 1/2 TRIDENT-1 study data demonstrate repotrectinib’s clinically meaningful response rates and durable clinical activity in patients with ROS1-positive non-small cell lung cancer


Data show...

Related Keywords

United States ,Hong Kong ,Taiwan ,Macau ,China ,Chinese ,Rafaelg Amado , ,Zai Lab Limited ,Drug Administration ,National Medical Products Administration ,Global Oncology Research ,Exchange Commission ,Zai Lab Forward ,Bristol Myers Squibb Company ,Zai Lab ,Bristol Myers Squibb ,New England Journal ,Point Therapeutics ,Turning Point Therapeutics ,Greater China ,Drug Evaluation ,New Drug Application ,Breakthrough Therapy Designations ,Private Securities Litigation Reform Act ,Thoracic Cancer January ,Markets ,